Recombinant SARS-CoV-2 RBD with a built in T helper epitope induces strong neutralization antibody response.
Vaccine
; 39(8): 1241-1247, 2021 02 22.
Article
in English
| MEDLINE | ID: covidwho-1039581
ABSTRACT
Without approved vaccines and specific treatments, COVID-19 is spreading around the world with above 26 million cases and approximately 864 thousand deaths until now. An efficacious and affordable vaccine is urgently needed. The Val308 - Gly548 of spike protein of SARS-CoV-2 linked with Gln830 - Glu843 of Tetanus toxoid (TT peptide) (designated as S1-4) and without TT peptide (designated as S1-5) were expressed and renatured. The antigenicity and immunogenicity of S1-4 were evaluated by Western Blotting (WB) in vitro and immune responses in mice, respectively. The protective efficiency was measured preliminarily by microneutralization assay (MN50). The soluble S1-4 and S1-5 protein was prepared to high homogeneity and purity. Adjuvanted with Alum, S1-4 protein stimulated a strong antibody response in immunized mice and caused a major Th2-type cellular immunity supplemented with Th1-type immunity. Furthermore, the immunized sera could protect the Vero E6 cells from SARS-CoV-2 infection with neutralizing antibody titer 256. Recombinant SARS-CoV-2 RBD with a built in T helper epitope could stimulate both strong humoral immunity supplemented with cellular immunity in mice, demonstrating that it could be a promising subunit vaccine candidate.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Epitopes, T-Lymphocyte
/
Spike Glycoprotein, Coronavirus
/
COVID-19 Vaccines
/
Antibodies, Viral
Type of study:
Experimental Studies
Topics:
Vaccines
Limits:
Animals
/
Female
/
Humans
Language:
English
Journal:
Vaccine
Year:
2021
Document Type:
Article
Affiliation country:
J.vaccine.2021.01.044
Similar
MEDLINE
...
LILACS
LIS